Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2006
SB-683699 is an oral medication that is thought to reduce the number of active white blood cells entering the brain; these white blood cells are part of the disease process for MS. This study will look at whether different doses of SB-683699 are effective and safe in patients with relapsing remitting MS.
Epistemonikos ID: 9704b10b7f058abef438a5c1632698ce66f6ef09
First added on: Mar 31, 2022